LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Search

Avita Therapeutics Inc

Cerrado

5 -6.89

Resumen

Variación precio

24h

Actual

Mínimo

4.96

Máximo

5.37

Métricas clave

By Trading Economics

Ingresos

1.6M

-12M

Ventas

554K

18M

BPA

-0.536

Margen de beneficios

-65.968

Empleados

226

EBITDA

1.6M

-9.7M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

-16.51% downside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

25M

149M

Apertura anterior

11.89

Cierre anterior

5

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Avita Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 feb 2026, 23:25 UTC

Acciones populares

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 feb 2026, 23:15 UTC

Ganancias

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 feb 2026, 23:54 UTC

Charlas de Mercado

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 feb 2026, 23:47 UTC

Ganancias

Ferrovial 4Q Net EUR197M >FER.MC

25 feb 2026, 23:45 UTC

Ganancias

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 feb 2026, 23:42 UTC

Ganancias

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 feb 2026, 23:38 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Company's Business Operations Remain Normal >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com FY EPS CNY47.67 >TCOM

25 feb 2026, 23:06 UTC

Ganancias

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 feb 2026, 23:01 UTC

Ganancias

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 feb 2026, 23:00 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

25 feb 2026, 23:00 UTC

Charlas de Mercado
Ganancias

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 feb 2026, 22:56 UTC

Charlas de Mercado
Ganancias

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 feb 2026, 22:43 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 feb 2026, 22:40 UTC

Charlas de Mercado
Ganancias

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 feb 2026, 22:40 UTC

Ganancias

Karoon Energy Says Search for New CFO Well Advanced

25 feb 2026, 22:39 UTC

Ganancias

Karoon Energy Says CFO Ray Church to Leave Company

25 feb 2026, 22:39 UTC

Ganancias

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 feb 2026, 22:38 UTC

Ganancias

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Comparación entre iguales

Cambio de precio

Avita Therapeutics Inc previsión

Precio Objetivo

By TipRanks

-16.51% descenso

Estimación a 12 Meses

Media 4.5 USD  -16.51%

Máximo 5.5 USD

Mínimo 3.5 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Avita Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

1

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.83 / 9.77Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
help-icon Live chat